225 related articles for article (PubMed ID: 34769200)
1. Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis.
Teng PC; Huang SP; Liu CH; Lin TY; Cho YC; Lai YL; Wang SC; Yeh HC; Chuu CP; Chen DN; Cheng WC; Li CY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769200
[TBL] [Abstract][Full Text] [Related]
2. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
3. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract][Full Text] [Related]
5. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract][Full Text] [Related]
6. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
7. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
9. A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.
Wang J; Jiang L; Shang Z; Ye Z; Yuan D; Cui X
Cancer Biother Radiopharm; 2024 May; 39(4):306-317. PubMed ID: 37610864
[No Abstract] [Full Text] [Related]
10. Comprehensive analysis of DNA damage repair in squamous cell carcinoma subtypes.
Qin F; Sun Y; Deng K; Qin J; Xu Z; Wei J; Yuan L; Zheng T; Li S
Life Sci; 2021 Aug; 278():119559. PubMed ID: 33932441
[TBL] [Abstract][Full Text] [Related]
11. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
12. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
13. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Aldea M; Lam L; Orillard E; Llacer Perez C; Saint-Ghislain M; Gravis G; Fléchon A; Roubaud G; Barthelemy P; Ricci F; Priou F; Neviere Z; Beaufils M; Laguerre B; Hardy AC; Helissey C; Ratta R; Borchiellini D; Pobel C; Joly F; Castro E; Thiery-Vuillemin A; Baciarello G; Fizazi K
Eur J Cancer; 2021 Dec; 159():87-97. PubMed ID: 34742160
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
17. Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome.
Swami N; Nguyen T; Ogobuiro I; Abramowitz M; Chipidza F; Davicioni E; Meiyappan K; Pra AD; Nguyen PL; Pollack A; Punnen S; Mahal BA; Alshalalfa M
Clin Genitourin Cancer; 2023 Feb; 21(1):76-83. PubMed ID: 36522269
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
[TBL] [Abstract][Full Text] [Related]
19. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract][Full Text] [Related]
20. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
